Suzhou Zhihe Biomedical Technology

SmartNuclide Biopharma is pioneering the development of innovative nuclear medicine treatments, focusing on targeted therapies that offer new hope to patients with cancer. Established in 2015 and located in Suzhou Industrial Park, the company is committed to leveraging cutting-edge technologies to develop diagnostic and therapeutic solutions that address unmet medical needs in oncology.

SmartNuclide’s primary innovation lies in its SRC (Single-domain Radiopharmaceuticals for Cancer) technology platform, which integrates single-domain antibodies with radionuclide technology to create novel biomolecular agents. These agents are designed to target specific cancer-related biomarkers, allowing for precise imaging and treatment of various cancer types.

The company's product pipeline includes several promising candidates:

SNA001: A recombinant human thyroid-stimulating hormone (rhTSH), enhances radioiodine therapy's efficacy in differentiated thyroid cancer, reducing treatment discomfort.

SNA002: A radiolabeled imaging agent targeting PD-L1, which is crucial for the non-invasive assessment of tumor PD-L1 expression and monitoring immunotherapy efficacy.

SNA006: A CD8+ T-cell imaging agent, offering insights into the immune system's activity within the tumor microenvironment, crucial for evaluating immunotherapeutic interventions.

SNA018: Details are less specified, but like its peers, it is aimed at enhancing the diagnosis and treatment of oncological diseases.

SmartNuclide is also recognized for its contribution to the scientific community, with multiple research papers published in esteemed journals, adding valuable knowledge to the field of nuclear medicine.